Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
177 results about "Isosorbide mononitrate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease).
Single nitrate isosorbide delayed-release tablets
InactiveCN1679536AEasy to takeHelp flushingPharmaceutical delivery mechanismCardiovascular disorderCoronary artery diseaseCoronary heart disease
A slow-releasing tablet of isosorbide mononitrate for treating coronary heart disease and angina pectoris is prepared proportionally from isosorbide mononitrate, slow releasing agent, adhesive, filler and lubricant through proportional mixing, granulating, and tabletting.
Owner:LUNAN PHARMA GROUP CORPORATION
Methods for treating blood disorders with nitric oxide donor compounds
The invention describes methods for treating blood disorders or for treating the symptoms and / or complications associated with blood disorders by administering a therapeutically effective amount of at least one nitric oxide donor compound and optionally at least one antioxidant, or a pharmaceutically acceptable salt thereof, and / or at least one therapeutic agent. The antioxidant is preferably a hydralazine compound or a pharmaceutically acceptable salt thereof. The nitric oxide donor compound is preferably N-hydroxy-L-arginine and / or isosorbide dinitrate and / or isosorbide mononitrate. The blood disorder is preferably sickle cell anemia. The complication resulting from a blood disorder is preferably pulmonary hypertension.
Owner:NITROMED
Compositions and Methods Using Apocynin Compounds and Nitric Oxide Donors
The invention describes novel compositions comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The invention also provides novel kits comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound, and, optionally, at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating gastrointestinal disorders; (h) treating inflammatory disorders; and (j) treating respiratory disorders. The apocynin compound may preferably be apocynin. The nitric oxide donor compound may preferably be isosorbide dinitrate and / or isosorbide mononitrate.
Owner:ARBOR PHARMA LLC
Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
InactiveUS7138430B2Prevention of platelet aggregation and platelet adhesionAntibacterial agentsBiocideMetaboliteAntioxidant
Owner:NICOX SA
Derivatives of isosorbide mononitrate and its use as vasodilating agents with reduced tolerance
InactiveUS6858632B2Potent vasodilating effectSmall and null tolerance effectBiocideOrganic chemistryArylTolerability
Novel derivatives of isosorbide mononitrate and its pharmaceutically acceptable salts, which have vasodilating activity with a reduced effect of tolerance, of the general formula (I) in which A and B independently represent any of the groups—ONO2 and —Z—CO—R, wherein Z is an oxygen atom or sulphur atom and R is an alkyl C1-C4 group, an aryl group or an aralkyl group, eventually substituted, or the group in which R1 is hydrogen, or an alkyl C1-C4 group, an aryl group or an aralkyl group, eventually substituted, with the proviso that one of A or B is always —ONO2, but never both of them at the same time, when Z is an sulphur atom R is an alkyl C1-C4 group, an aryl group or an aralkyl group, eventually substituted, and when Z is an oxygen atom R is the group
Owner:LACER SA
Isosorbide mononitrate timely quick-release and slow-release preparation
ActiveCN101143140AImprove stabilityEffective plasma concentration stablePharmaceutical non-active ingredientsGranular deliveryControl layerMedicine
The invention discloses a time quick-release and slow-release preparation of isosorbide mononitrate. The technical problem for the invention to solve is to provide a time quick-release and slow-release preparation, which is provided with long time of retaining the effective plasma-drug concentration and a low interval of 5-ISMN plasma-drug concentration. Each structure layer of the invention is orderly arranged from the inside to the outside as a parent nuclear of a pill core, a drug layer of a second dosage, an insulating layer, a slow-release coating layer, a drug layer of a first dosage, an expanding layer and a release controlling layer. The weight percentages of each layer are 15 to 40 percent of the parent nuclear of the pill core, 0.3 to 5.7 percent of the drug layer of the second dosage, 0 to 20 percent of the insulating layer, 5 to 40 percent of the slow-release coating layer, 0.7 to 13.4 percent of the drug layer of the first dosage, 5 to 30 percent of the expanding layer and 5 to 40 percent of the release controlling layer. The invention combines the characteristics of a time quick-release and slow-release medication system to avoid the drug resistance as well as accurately meet the clinical requirement of the angina treatment of the patient of the coronary heart disease.
Owner:SHANGAI PHARMA GRP CO LTD +1
Method for synthesizing and purifying 5-isosorbide mononitrate
The invention provides a method for synthesizing and purifying 5-isosorbide mononitrate. The method comprises the steps of: (1) preparing a nitrifying reagent from concentrated nitric acid, acetic acid and acetic anhydride, and directly nitrifying isosorbide to obtain an isosorbide nitride mixture; (2) adding water to arouse a quenching reaction, separating out 2,5-isoscrbide dinifrate at a temperature ranging from 0 to 5 DEG C, and filtering out the 2,5-isoscrbide dinifrate; (3) reacting the filtrate with sodium hydroxide to prepare an isosorbide mononitrate sodium salt aquo-complex, filtering, and hydrolyzing the sodium salt; and (4) extracting, concentrating and recrystallizing to obtain high-purity 5-isosorbide mononitrate. The preparation method provided by the invention is simple, safe, easy to operate and short in reaction period; impurities are easy to remove, and the yield and the purity are high; therefore, the method lays a foundation for industrial production.
Owner:QINGDAO HUANGHAI PHARM CO LTD
Preparation process of isosorbide mononitrate
InactiveCN1618798AHarsh reaction conditionsLow yieldOrganic chemistryCardiovascular disorderAnginaAcetic oxide
A process for preparing the isosorbide mononitrate from sorbitol includes dewatering sorbitol by p-methylphenyl sulfonic acid to obtain anhydrosorbitol, protecting by acetic oxide under existance of N,N-dimethylaminopyridine, nitrating by nitric acid / acetic oxide / acetic acid system, and removing protection by potassium carbonate-methanol system. It can be used to treat angina pectoris.
Owner:LUNAN PHARMA GROUP CORPORATION
Compositions and methods related to heart failure
InactiveUS20060014828A1Reduce in quantityShorten the construction periodBiocideNervous disorderDiseaseType B Natriuretic Peptide
The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays (i.e., two or more hospital stays); (e) reducing the number of hospital admissions for heart failure; (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and / or the number of hospital visits); (g) increasing the left ventricular ejection fraction in a heart failure patient; (h) treating a sexual dysfunction (e.g., erectile dysfunction and female sexual dysfunction) (j) treating a headache in a heart failure patient by administering a non-steroidal antiinflammatory compound (i.e., NSAIDs); (k) treating a heart failure patient who has a history of hypertension (but who is not currently diagnosed with hypertension); (l) improving the quality of life in a heart failure patient based on the Minnesota Living with heart failure questionnaire; (m) decreasing the levels of B-type natriuretic peptide; (n) treating hypertension in a heart failure patient; (o) lowering blood pressure in a heart failure patient; (p) treating labile hypertension; (q) treating idiopathic hypertension; (r) increasing patient compliance with medication dosing in a heart failure patient; (s) treating hypertension in a patient with a dilated heart; (t) treating ischemic disease and / or coronary artery disease; and (u) reducing cardiomegaly in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and / or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.
Owner:NITROMED
Prepn process of isosorbide mononitrate
ActiveCN1609108ALow boiling pointReduce the temperatureOrganic chemistryCardiovascular disorderRutheniumIsosorbide mononitrate
The preparation process of isosorbide mononitrate as angina pectoris resisting medicine includes the following steps: directly nitrating sorbitol with fuming nitric acid and concentrated sulfuric acid in 0-0.5 time to obtain 2, 5-dinitro isosorbate; and the subsequent catalytic hydrogenation with ruthenium complex as catalyst and selective reduction of 2-nitro group. The present invention has simple process and high yield.
Owner:SHANDONG NEWTIME PHARMA
A kind of isosorbide mononitrate controlled release preparation and preparation method thereof
ActiveCN102293760AGood treatment effectAvoid drug resistancePill deliveryPharmaceutical non-active ingredientsEngineeringDrug release
The invention discloses an isosorbide mononitrate timing controlled release preparation and a preparation method thereof. The isosorbide mononitrate timing controlled release preparation of the present invention has certain time-lag and long-acting stationary release, and comprises a semi-permeable membrane with drug release apertures, an isolating coating and a double layer label including a drug contained layer and a boosting layer. The isosorbide mononitrate timing controlled release preparation of the present invention is an osmotic pump tablet with certain time-lag and long-acting stationary release, and can provide a more lasting and stationary plasma concentration and is bioequivalent compared with a sale long-acting preparation Elantan.
Owner:SHANGAI PHARMA GRP CO LTD
Tablet of isosorbide mononitrate
ActiveCN101732276AEasy to pumpStable release ratePill deliveryHeterocyclic compound active ingredientsMedicineSemipermeable membrane
The invention relates to a tablet of isosorbide mononitrate, in particular to a double-layer osmotic pump controlled release tablet of isosorbide mononitrate, which belongs to the field of medicine preparation. A single-chamber double-layer osmotic pump tablet of the isosorbide mononitrate is characterized in that a semi-transparent coating film cover a double-layer core body consisting of a medicine-containing layer and a boosting layer; and the coating film is provided with a medicine releasing pore on the surface of the medicine-containing layer. The gastrointestinal tract water enters a double-layer tablet chip through the semi-transparent film; the medicines forms a mixed suspension liquid or solution when contacting water in the medicine-containing layer; a penetration enhancer enables the solution of the medicine-containing layer to be hypertonic so that an osmotic pressure difference exists between the inner side and the outer side of the film, which is beneficial to pumping the medicines out; and the pressure is generated in the boosting layer through water absorption, dissolution and expansion of a penetrating agent so as to further boost a medicine liquid to eject the pore.
Owner:LUNAN BETTER PHARMA
Isosorbide mononitrate sustained-release pallets, preparation prepared from same and preparation method for isosorbide mononitrate sustained-release pallets
ActiveCN103610650AStable in natureQuality improvementPharmaceutical non-active ingredientsGranular deliverySustained release pelletsAdhesive
The invention relates to the field of medicaments, and in particular relates to isosorbide mononitrate sustained-release pallets, a preparation prepared from the same and a preparation method for the isosorbide mononitrate sustained-release pallets. Each sustained-release pallet consists of a blank pallet core, a medicament-carrying layer, a sustained-release layer and a quick-release layer, wherein the medicament-carrying layer consists of isosorbide mononitrate, a first filling agent and a first adhesive; the sustained-release layer consists of a sustained-release material, a pore-forming agent, an anti-sticking agent, a plasticizer and a second adhesive; the quick-release layer consists of isosorbide mononitrate, a second filling agent and a third adhesive. The isosorbide mononitrate sustained-release pallets and the preparation prepared from the same are stable in property, reliable in quality and high in bioavailability, remarkable changes in the in-vitro release of a medicament caused by the crystallization of isosorbide mononitrate can be avoided, and the stability of the isosorbide mononitrate sustained-release pallets and the preparation prepared from the same is improved.
Owner:珠海润都制药股份有限公司
Single nitrate isosorbide sodium chloride injection
InactiveCN1679537AFast and reliableGood curative effectPharmaceutical delivery mechanismHeterocyclic compound active ingredientsCoronary artery diseaseAngina
A liquid sodium chloride injection of isosorbide mononitrate for treating coronary heart disease and angina pectoris is prepared from isosorbide mononitrate and sodium chloride. It can quickly take its high curative effect.
Owner:LUNAN PHARMA GROUP CORPORATION
Isosorbide mononitrate sustained release tablet and preparation method thereof
ActiveCN102688212APharmaceutical non-active ingredientsDrageesSustained Release TabletIsosorbide mononitrate
The invention belongs to the field of pharmaceutic preparation, and particularly relates to an isosorbide mononitrate sustained release tablet and a preparation method thereof. The tablet prescription of the sustained release tablet in the application comprises the following components: isosorbide mononitrate, hydroxypropyl methylcellulose K4M, microcrystalline cellulose, silicon dioxide and sodium dodecyl sulfate. The isosorbide mononitrate sustained release tablet prepared by the components has better stability.
Owner:北京均大检测科技有限公司
Isosorbide mononitrate sustained-release tablet and preparation method thereof
InactiveCN102416005AResidue reductionLower dosePharmaceutical delivery mechanismCardiovascular disorderProlonged-release tabletImmediate release
The invention relates to an isosorbide mononitrate sustained-release tablet and a preparation method thereof, belonging to the technical field of medicinal preparations. The sustained-release tablet comprises a coating of isosorbide mononitrate drug loaded microballoons which account for 48% to 55% of the total weight of the tablet and a quick-release layer which accounts for 45% to 52% and comprises isosorbide mononitrate, a binder, a filler and a lubricant. According to the invention, isosorbide mononitrate is divided into two parts, i.e., the part of quick release and the part of sustained release, which enables the tablet to take effect rapidly at an initial stage of administration, maintain an effective plasma concentration after the effective plasma concentration is reached and retain the effective plasma concentration at a low level so as to reduce residual quantity of the tablet at administration time of the tablet the next day, thereby effectively avoiding generation of drug resistance.
Owner:NANJING CHENGONG PHARM CO LTD
Methods for reducing hospitalizations related to heart failure
InactiveUS20060014829A1Reduce in quantityShorten the construction periodBiocideNervous disorderDigitalisMortality rate
The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays; (e) reducing the number of hospital admissions for heart failure; and (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and / or the number of hospital visits) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and / or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.
Owner:NITROMED
Isosorbide mononitrate osmotic pump type controlled release formulation and preparation method thereof
InactiveCN101342151AImprove complianceThe effect of small individual differencesPharmaceutical delivery mechanismCardiovascular disorderSide effectExcipient
The invention relates to an isosorbide mononitrate osmotic pump type controlled release preparation and a preparation method thereof. The osmotic pump type controlled release preparation is composed of a tablet core and semipermeable film coating with medicine releasing holes; wherein, the tablet core is composed of isosorbide mononitrate, penetration enhancer, bond and other excipient, and the semipermeable film includes coating material and plasticizer; the punching mode includes mechanical drilling and laser drilling. The preparation of the invention can effectively control the constant speed release rate of medicine and has the advantages of few administration times, less side effect, long efficacy lasting time, avoidance of medicine tolerance, etc.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism
InactiveUS20090192128A1Reduce mortalityIncreased oxygen consumptionBiocideMicrobiological testing/measurementAntioxidantLeft ventricular size
The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and / or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and / or isosorbide mononitrate.
Owner:NITROMED +1
Preparation method for isosorbide 5-mononitrate
ActiveCN104892623AHigh yieldReduce manufacturing costOrganic chemistryIsosorbide-5-mononitrateSolvent
The invention provides a preparation method for isosorbide 5-mononitrate. The preparation method comprises the following steps: with isosorbide dinitrate as a raw materials and Pd / C as a catalyst in a special mixed solvent, carrying out selective hydrogenation reduction on 2-nitro, filtering after reaction, steaming to remove ethyl alcohol in filtrate, extracting residual concentrated liquid through ethyl acetate, washing extracting liquid through dilute acid, washing to be neutral through water, drying through anhydrous magnesium sulfate, filtering to remove a drying agent and steaming to remove ethyl acetate so as to obtain high-purity isosorbide 5-mononitrate. Compared with the prior art, the synthetic method provided by the invention is simple and easy to operate, impurities are easy to remove, the yield and purity are higher, the cost is reduced since the Pd / C and the solvent can be recycled and reused, isosorbide generated through over reduction can be recycled and the preparation method is suitable for industrial production.
Owner:SHANDONG NEWTIME PHARMA
Isosorbide mononitrate sustained-release pellet, and isosorbide mononitrate quick-release and sustained-release pellet capsule adopting it
ActiveCN103211768AAccelerated agingReduce permeabilityPharmaceutical non-active ingredientsGranular deliverySustained release pelletsMedicine
The invention relates to an isosorbide mononitrate sustained-release pellet, and an isosorbide mononitrate quick-release and sustained-release pellet capsule adopting it. The sustained-release film of the sustained-release pellet adopts Eurdragit RS 30D as a film forming material, the core of the sustained-release pellet contains high-expansibility sodium carboxymethyl starch and a pharmaceutically-acceptable excipient commonly used for sustained-release pellets, and optimally, the excipient is microcrystalline cellulose, wherein the weight percentage of sodium carboxymethyl starch in the core of the sustained-release pellet is 5-20%. The sustained-release film of the sustained-release pellet includes the Eurdragit RS 30D, a plasticizer triethyl citrate and an anti-adherent talcum powder, the optimal ratio of the Eurdragit RS 30D to triethyl citrate to the talcum powder is 30:3:4, and the optimal coating weight gain is 19-38%. The core will obviously expand after absorbing water because of the containment of sodium carboxymethyl starch highly expanding after contacting with water, so the sustained-release film is stretched, the thickness of the film is thinned, the apertures of water-pervious micro-pores are increased, the permeability is good, and the permeability decrease caused by film ageing is compensated, thereby the middle and later stage release speed is basically constant, the last stage residue is small, and a stable release performance is always maintained prior to the expiration date.
Owner:北京天衡药物研究院有限公司
Isosorbide mononitrate sustained release tablets and preparation process thereof
InactiveCN104644589AStable drug releaseGood drug release stabilityPharmaceutical delivery mechanismPharmaceutical non-active ingredientsSustained Release TabletFoaming agent
The invention discloses isosorbide mononitrate sustained release tablets and a preparation process thereof. According to the preparation, the sustained release aim is achieved by adopting a method for combining mesoporous carbon and membrane controlled coating. The process comprises the following steps: preparing a mesoporous carbon-isosorbide mononitrate complex; by taking ethyl cellulose as a sustained release coating material and taking hydroxyethyl cellulose as a pore-foaming agent, performing bottom-spray coating by adopting a fluidized bed to obtain sustained release coated pills; and mixing the pills with other pharmaceutically acceptable auxiliary materials, and pressing into the tablets. The sustained release tablets disclosed by the invention have the advantages that the drug release is stable, membrane aging is avoided in the storage process, the drug release stability is high, the bioavailability is high, and the preparation process is simple.
Owner:王加峰
Compound isosorbide mononitrate aspirin sustained-release capsule preparation and preparation method
ActiveCN103285017AReduce adverse reactionsAvoid adverse reactionsPharmaceutical delivery mechanismHeterocyclic compound active ingredientsSustained release pelletsSustained Release Capsule
The invention discloses a compound isosorbide mononitrate aspirin sustained-release capsule preparation. The compound isosorbide mononitrate aspirin sustained-release capsule preparation is characterized by comprising an isosorbide mononitrate sustained-release capsule preparation and an aspirin enteric-coated preparation, wherein the isosorbide mononitrate sustained-release capsule preparation contains 40-80 parts by weight of isosorbide mononitrate and comprises an immediate-release pellet with 30 percent of isosorbide mononitrate and a sustained-release pellet with 70 percent of isosorbide mononitrate, and the aspirin enteric-coated preparation contains 50-90 parts by weight of aspirin. The invention also provides a preparation method of the compound capsule preparation. With the adoption of the compound isosorbide mononitrate aspirin sustained-release capsule preparation, the curative effects are better improved, the adverse reaction due to stimulation from the aspirin to a gastric mucosa is better reduced, and meanwhile, the isosorbide mononitrate can also satisfy the requirement of stable release in a stomach.
Owner:吉林天衡药业有限公司
Isosorbide mononitrate sodium chloride injection
ActiveCN101708157AEnsure safetyEnsure effectivenessInorganic non-active ingredientsPharmaceutical delivery mechanismSodium Chloride InjectionIsosorbide mononitrate
The invention relates to isosorbide mononitrate sodium chloride injection which belongs to the field of medical preparation. The isosorbide mononitrate sodium chloride injection is prepared from 10-40mg of isosorbide mononitrate, 450-1800mg of sodium chloride, an amount of pH regulator which regulates the pH to 4.0-7.0 and water for injection, wherein the volume of the water for injection is fixed to 100ml. The isosorbide mononitrate sodium chloride injection has high stability and simple preparation process.
Owner:LUNAN PHARMA GROUP CORPORATION
Isosorbide mononitrate freeze-dried power injection and preparation method thereof
ActiveCN101816636ARecovery propertiesLoose texturePowder deliveryPharmaceutical non-active ingredientsAlcoholClinical efficacy
The invention belongs to the technical field of pharmaceutical preparation and provides an isosorbide mononitrate freeze-dried power injection and a preparation method thereof. In the preparation process of the isosorbide mononitrate freeze-dried power injection of the invention, sorbic alcohol is used as a propping agent and the pH value of the solution of a middle body is adjusted to between 6.5 and 7.5 by acidic or alkaline buffer solution, so the hydrolysis of a main medicament is restrained and the stability of the main medicament is improved; and a pre-freezing initial temperature is controlled to be below 50 DEG C below zero, and the second sublimation temperature in a free-drying process is controlled to be between 5 and 15 DEG C, so the medicament content and the stability of related substances are improved. The stable isosorbide mononitrate freeze-dried power injection prepared by the method has reduced toxicity and good clinical effects.
Owner:鲁南新时代生物技术有限公司
Isosorbide mononitrate sustained release tablet and preparation method thereof
ActiveCN110403911AImprove liquidityPharmaceutical non-active ingredientsPill deliverySustained Release TabletLactose
The invention belongs to the field of pharmaceutical preparations, and particularly discloses a large-sized isosorbide mononitrate sustained release tablet and a preparation method thereof. Accordingto the prescription, the sustained release tablet is prepared from the components: isosorbide mononitrate:lactose (6:4), hydroxypropyl methylcellulose K200M, microcrystalline cellulose, mannitol, hydrogenated castor oil, silica and magnesium stearate. According to the large-sized isosorbide mononitrate sustained release tablet and the preparation method thereof, the microcrystalline cellulose, themannitol and the hydrogenated castor oil of a certain proportion are mixed to greatly improve the fluidity of mixed powder, and requirements of producing pressed tablets are met.
Owner:LUNAN PHARMA GROUP CORPORATION
Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use
InactiveUS20060009513A1Prevention of platelet aggregation and platelet adhesionAntibacterial agentsBiocideMetaboliteAntioxidant
The invention describes novel compositions comprising nebivolol and / or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and / or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and / or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and / or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and / or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and / or preventing Raynaud's syndrome; and for treating and / or preventing cardiovascular diseases or disorders.
Owner:NICOX SA
Novel isosorbide mononitrate injection
ActiveCN101167717AHigh purityReduce contentInorganic non-active ingredientsCardiovascular disorderPhosphateBULK ACTIVE INGREDIENT
The invention provides a novel isosorbide mononitrate injection composition containing 1,2-propylene glycol and phosphate buffer and a preparation method thereof. Phosphate buffer is used to adjust the pH of the injection to 6.8-7.9. The injection prepared by the application of the invention improves the purity of the effective components of the medicine, reduces the content of related substances, and reduces the toxicity at the same time.
Owner:LUNAN PHARMA GROUP CORPORATION
Method for synthesizing 5-isosorbide mononitrate by aid of micro-channel reactors
ActiveCN108610350AShorten the diffusion distanceMass transfer speedOrganic chemistryAfter treatmentIsosorbide mononitrate
The invention belongs to the field of medicine synthesis, and particularly discloses a method for synthesizing 5-isosorbide mononitrate by the aid of micro-channel reactors. The method includes pumping nitrification reagents and isosorbide liquid into the micro-channel reactors and carrying out hybrid reaction; allowing products to flow out from outlets of the micro-channel reactors after the reaction is completely carried out; carrying out after-treatment on the products and separating and purifying the products to obtain the 5-isosorbide mononitrate which is a target product. The method hasthe advantages that the method is short in reaction time and is safe as compared with the traditional processes, and the yield of the 5-isosorbide mononitrate can be greatly increased.
Owner:LUNAN PHARMA GROUP CORPORATION
Isosorbide mononitrate sustained release tablet and preparation method thereof
ActiveCN110420192AGood sustained release effectImprove liquidityPill deliveryOil/fats/waxes non-active ingredientsSustained Release TabletWestern medicine
The invention belongs to the technical field of Western medicine preparations, and particularly provides an isosorbide mononitrate sustained release tablet and a preparation method thereof. Accordingto the prescription, the sustained release tablet comprises isosorbide mononitrate, lactose, sustained release materials, microcrystalline cellulose, a glidant and a lubricant. An isosorbide mononitrate mixed powder prepared by a special preparation process according to the formula has good fluidity and is suitable for direct tablet compression, and the prepared sustained release tablet is good instability and better in sustained release effect.
Owner:LUNAN PHARMA GROUP CORPORATION
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com